This 2-part, case-based activity focuses on several practical aspects of the management of relapsing-remitting multiple sclerosis. Highlights from the first case scenario include risk stratification for conversion to MS in patients who present with clinically isolated syndrome, as well as treatment selection for first-line therapy in the RRMS population. The second case study emphasizes the management of patients who are nonresponsive to first-line immunomodulating therapy. The potential role of emerging therapies for the treatment of this disease is also summarized.

Upon completion of this activity, participants will be able to:

• Assess patient risk for conversion to RRMS based on baseline MRI measurements at the time of clinical isolated syndrome presentation
• Review available immunomodulating therapies for the management of RRMS
• Propose potential strategies for the management of patients with RRMS who are nonresponsive to first-line immunomodulating therapy
• Analyze emerging immunomodulating therapies developed to improve outcomes in patients with RRMS

This activity has been designed to meet the educational needs of neurologists, advanced practice nurses, and other clinicians who provide care for patients with RRMS.

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CNE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media:

Internet

Release and Expiration Dates:

October 01, 2009 - September 30, 2010

Time to Complete:

60 minutes

Timothy Vollmer, MD
Professor of Neurology
Medical Director, Rocky Mountain MS Center
University of Colorado
Denver, Colorado

Timothy Vollmer, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Biogen Idec Inc. and TEVA Pharmaceuticals USA.
Grant/Research Support from Acorda Therapeutics Inc.; Bayer HealthCare Pharmaceuticals; Biogen Idec Inc.; Eli Lilly and Company; Serono, Inc.; and TEVA Pharmaceuticals USA.

Barry A. Singer, MD
Director of the MS Center for Innovations in Care
Missouri Baptist Medical Center
St. Louis, Missouri

Barry A. Singer, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bayer HealthCare Pharmaceuticals; Biogen Idec Inc.; EMD Serono, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc; and TEVA Pharmaceuticals USA.
Grant/Research Support from EMD Serono, Inc.; Genzyme Corporation; Novartis Pharmaceuticals Corporation; and sanofi-aventis.
Speakers Bureau participant with Bayer HealthCare Pharmaceuticals; Biogen Idec Inc.; EMD Serono, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc; and TEVA Pharmaceuticals USA.

Andrew F. Leuchter, MD
Professor, Department of Psychiatry and Biobehavioral Science
David Geffen School of Medicine at UCLA
Director, Laboratory of Brain, Behavior, and Pharmacology
Semel Institute for Neuroscience and Human Behavior at UCLA
Los Angeles, California

Andrew F. Leuchter, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Aspect Medical Systems; AstraZeneca, Ltd.; Eli Lilly and Company; GlaxoSmithKline; MEDACorp; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Shire Pharmaceuticals Group plc; and Takeda Pharmaceuticals North America, Inc.
Grant/Research Support from Aspect Medical Systems; Eli Lilly and Company; MedAvante, Inc.; Merck & Co., Inc.; National Center for Complementary and Alternative Medicine; National Institute of Mental Health; Novartis Pharmaceuticals Corporation; Pfizer Inc; VivoMetrics; and Wyeth Pharmaceuticals Inc.
Speakers Bureau participant with Eli Lilly and Company and Wyeth Pharmaceuticals Inc.
Shareholder in Aspect Medical Systems.
Advisory Board for Aspect Medical Systems; AstraZeneca, Ltd.; Eli Lilly and Company; GlaxoSmithKline; MEDACorp; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Shire Pharmaceuticals Group plc; and Takeda Pharmaceuticals North America, Inc.

Edwin Amos, MD
Clinical Professor of Neurology
David Geffen School of Medicine at UCLA
Los Angeles, California

Edwin Amos, MD, currently has no financial interests/relationships or affiliations in relation to this activity.

Andrew Leuchter, MD
David Geffen School of Medicine at UCLA
Semel Institute for Neuroscience and Human Behavior at UCLA
Los Angeles, California

Kirk A. Tacka, PhD
PVI, PeerView Institute for Medical Education, Inc.

Kirk A. Tacka, PhD, currently has no financial interests/relationships or affiliations in relation to this activity.

Physicians

This program was developed and reviewed by faculty members of the David Geffen School of Medicine at UCLA. This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Institute for Medical Education and the Semel Institute for Neuroscience and Human Behavior at UCLA, in association with PVI, PeerView Institute for Medical Education. The Institute for Medical Education takes responsibility for the content, quality and scientific integrity of this CME activity.

The Institute for Medical Education designates this educational activity for a maximum of 1.0 hour of AMA PRA Category 1 Credit^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. This credit may also be applied to the CMA Certification in Continuing Medical Education.

Nurses

The Semel Institute at UCLA is an accredited provider for continuing education credits for nurses (provider number CEP381). This course meets the qualifications for 1.0 hour of credit as required by the Board of Registered Nursing.

This activity is supported by an educational grant from